SCHEMBL973286

SCHEMBL973286

O=C(Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1)c1ccccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.70
MEN1 O00255 7/20 0.70
KDM4E B2RXH2 3/20 0.70
ALDH1A1 P00352 4/20 0.62
LMNA P02545 4/20 0.62
GAA P10253 1/20 0.62
MAPT P10636 1/20 0.62
SLC12A2 P55011 1/20 0.62
SLC12A5 Q9H2X9 1/20 0.62
KCNA5 P22460 1/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
GPR27 Q9NS67 4/20 0.57
PRMT1 Q99873 1/20 0.57
SLC10A2 Q12908 1/20 0.56
SLC10A1 Q14973 1/20 0.56
SLC10A6 Q3KNW5 1/20 0.56
BDKRB1 P46663 1/20 0.56
HTT P42858 2/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861391 0.84 MEN1 (0.72) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL14267570 0.83 MEN1 (0.73) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL13186467 0.82 KMT2A (0.77) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5125023 0.82 MEN1 (0.69) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL18132514 0.81 LMNA (0.72) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL5124321 0.80 MEN1 (0.66) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL7126135 0.80 MEN1 (0.69) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL7123083 0.79 MEN1 (0.67) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL5119195 0.79 MEN1 (0.67) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL6755857 0.78 KMT2A (0.74) KMT2AMEN1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518998-B2 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-27 US disclosed
CN-101815514-B Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI AVENTIS DEUTSCHLAND 2012-05-09 CN disclosed
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-27 US disclosed
CN-101815514-A Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI AVENTIS DEUTSCHLAND 2010-08-25 CN disclosed
EP-2207541-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN Sanofi-Aventis Deutschland GmbH (DE) 2010-07-21 EP disclosed
WO-2009043495-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SCN1A, SCN2A, CACNA1A KMT2A 568/4885MEN1 3830/4885KDM4E 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.